BioMarin Pharmaceutical Inc
BMRNHealthcare|Biotechnology|USA
$56.02
-0.20 (-0.35%)
DCF (FCF)
$37.55
Tangible Book
$29.52
Graham Number
$45.74
Earnings Power
$19.68
Upcoming Data Readouts (22)
Sep 2026
Est. completion
P1P2Duchenne Muscular Dystrophy
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
NCT06280209n=18
Mar 2027
Est. completion
P2Short Stature Homeobox- Containing Gene SHOX Deficiency
A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
NCT06668805n=54
Jul 2027
Est. completion
P1Claudication, Intermittent
The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication
NCT04800692n=10
Nov 2027
Est. completion
P1Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
NCT05734196n=16
Dec 2027
Est. completion
P2Achondroplasia
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
NCT04554940n=20
Dec 2027
Est. completion
P2Achondroplasia
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
NCT02724228n=30
Dec 2027
Est. completion
Feb 2028
Est. completion
Jun 2028
Est. completion
P2Hypochondroplasia
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262n=60
Sep 2028
Est. completion
P3Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency
NCT07473973n=12
Nov 2028
Est. completion
P1P2Hereditary Angioedema
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
NCT05121376n=44
Dec 2028
Est. completion
Phenylketonurias
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
NCT04404530n=45
Apr 2029
Est. completion
P1P2Hemophilia A With Inhibitor
Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors
NCT04684940n=10
Aug 2030
Est. completion
Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Cerliponase Alfa Observational Study in the US
NCT04476862n=35
Dec 2030
Est. completion
Jun 2031
Est. completion
P3Achondroplasia
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
NCT03424018n=119
Oct 2032
Est. completion
Phenylketonuria, Maternal
A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding
NCT05579548n=50
Nov 2033
Est. completion
Phenylketonuria (PKU)
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
NCT05813678n=450
Nov 2033
Est. completion
Phenylketonuria (PKU)
A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
NCT06305234n=200
May 2038
Est. completion
P2Achondroplasia
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
NCT03989947n=73
Awaiting Results (4)
Trials past primary completion date but still active — data readout may be imminent.
Aug 2026
P4
Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
NCT06780332Aug 2026
P3
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
NCT06455059Apr 2025
P3
Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
NCT06224907Jan 2025
P3
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
NCT05270837